Shortages of Ozempic and Wegovy which were in place for greater than two years have been resolved, as provides of the favored diabetes and weight problems remedies proceed to enhance, federal regulators mentioned Friday.
The drugmaker Novo Nordisk can meet present and future demand within the U.S., the Meals and Drug Administration mentioned. However sufferers should see some provide disruptions because the medicines transfer from the producer to distributors after which to pharmacies.
The injectable medicine have been in scarcity since 2022.
Compounding pharmacies and different entities which were allowed to make and distribute off-brand copies of the medicine throughout the scarcity must wind down manufacturing within the subsequent few months, the FDA mentioned.
In December, the company mentioned the identical factor when it declared that shortages had ended for Eli Lilly and Co.’s Zepbound and Mounjaro. Zepbound is authorized to deal with weight problems and Mounjaro is authorized for diabetes. They use the identical energetic ingredient, tirzepatide.
Ozempic, for diabetes, and Wegovy, for weight reduction, use the energetic ingredient semaglutide.
All 4 medicine are a part of a GLP-1 class of remedies that has proven unprecedented outcomes for serving to folks shed weight by lowering urge for food and boosting emotions of fullness.
Gross sales have soared for the medicine in recent times. However the shortages and challenges with insurance coverage protection have made it troublesome for a lot of sufferers to get the medicine.
___
The Related Press Well being and Science Division receives help from the Howard Hughes Medical Institute’s Science and Instructional Media Group and the Robert Wooden Johnson Basis. The AP is solely accountable for all content material.
Copyright © 2025 by The Related Press. All Rights Reserved.
